Novel targeted therapies for inflammatory bowel disease

Research output: Contribution to journalReviewResearchpeer-review

Standard

Novel targeted therapies for inflammatory bowel disease. / Coskun, Mehmet; Vermeire, Severine; Nielsen, Ole Haagen.

In: Trends in Pharmacological Sciences, Vol. 38, No. 2, 02.2017, p. 127-142.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Coskun, M, Vermeire, S & Nielsen, OH 2017, 'Novel targeted therapies for inflammatory bowel disease', Trends in Pharmacological Sciences, vol. 38, no. 2, pp. 127-142. https://doi.org/10.1016/j.tips.2016.10.014

APA

Coskun, M., Vermeire, S., & Nielsen, O. H. (2017). Novel targeted therapies for inflammatory bowel disease. Trends in Pharmacological Sciences, 38(2), 127-142. https://doi.org/10.1016/j.tips.2016.10.014

Vancouver

Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends in Pharmacological Sciences. 2017 Feb;38(2):127-142. https://doi.org/10.1016/j.tips.2016.10.014

Author

Coskun, Mehmet ; Vermeire, Severine ; Nielsen, Ole Haagen. / Novel targeted therapies for inflammatory bowel disease. In: Trends in Pharmacological Sciences. 2017 ; Vol. 38, No. 2. pp. 127-142.

Bibtex

@article{bb01ceac21ea4486a5befd36743f6533,
title = "Novel targeted therapies for inflammatory bowel disease",
abstract = "Our growing understanding of the immunopathogenesis of inflammatory bowel disease (IBD) has opened new avenues for developing targeted therapies. These advances in treatment options targeting different mechanisms of action offer new hope for personalized management. In this review we highlight emerging novel and easily administered therapeutics that may be viable candidates for the management of IBD, such as antibodies against interleukin 6 (IL-6) and IL-12/23, small molecules including Janus kinase inhibitors, antisense oligonucleotide against SMAD7 mRNA, and inhibitors of leukocyte trafficking to intestinal sites of inflammation (e.g., sphingosine 1-phosphate receptor modulators). We also provide an update on the current status in clinical development of these new classes of therapeutics.",
author = "Mehmet Coskun and Severine Vermeire and Nielsen, {Ole Haagen}",
note = "Copyright {\circledC} 2016 Elsevier Ltd. All rights reserved.",
year = "2017",
month = "2",
doi = "10.1016/j.tips.2016.10.014",
language = "English",
volume = "38",
pages = "127--142",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Ltd. * Trends Journals",
number = "2",

}

RIS

TY - JOUR

T1 - Novel targeted therapies for inflammatory bowel disease

AU - Coskun, Mehmet

AU - Vermeire, Severine

AU - Nielsen, Ole Haagen

N1 - Copyright © 2016 Elsevier Ltd. All rights reserved.

PY - 2017/2

Y1 - 2017/2

N2 - Our growing understanding of the immunopathogenesis of inflammatory bowel disease (IBD) has opened new avenues for developing targeted therapies. These advances in treatment options targeting different mechanisms of action offer new hope for personalized management. In this review we highlight emerging novel and easily administered therapeutics that may be viable candidates for the management of IBD, such as antibodies against interleukin 6 (IL-6) and IL-12/23, small molecules including Janus kinase inhibitors, antisense oligonucleotide against SMAD7 mRNA, and inhibitors of leukocyte trafficking to intestinal sites of inflammation (e.g., sphingosine 1-phosphate receptor modulators). We also provide an update on the current status in clinical development of these new classes of therapeutics.

AB - Our growing understanding of the immunopathogenesis of inflammatory bowel disease (IBD) has opened new avenues for developing targeted therapies. These advances in treatment options targeting different mechanisms of action offer new hope for personalized management. In this review we highlight emerging novel and easily administered therapeutics that may be viable candidates for the management of IBD, such as antibodies against interleukin 6 (IL-6) and IL-12/23, small molecules including Janus kinase inhibitors, antisense oligonucleotide against SMAD7 mRNA, and inhibitors of leukocyte trafficking to intestinal sites of inflammation (e.g., sphingosine 1-phosphate receptor modulators). We also provide an update on the current status in clinical development of these new classes of therapeutics.

U2 - 10.1016/j.tips.2016.10.014

DO - 10.1016/j.tips.2016.10.014

M3 - Review

C2 - 27916280

VL - 38

SP - 127

EP - 142

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 2

ER -

ID: 172433342